Cerebrolysin

• Scientifically supportable uses include hydrolysate fingerprint method development, peptide-size-distribution and amino-acid profiling, batch-comparability studies, cell-based neurobiology assays with appropriate reference material and evaluation of how source or process variables affect a complex mixture
• Clinical trial outcomes apply only to the studied finished formulations and protocols.

CAS

12656-61-0

Formula

Not applicable — mixture or multi-component material

Molecular weight

Confirm supplied form on batch COA

Appearance

Lot- and presentation-specific research material; confirm physical form, colour, clarity or cake condition on the released-lot documents

Purity

Not expressible as a single percentage; require composition fingerprint, quantitative content and process-specific acceptance criteria · target, verify batch COA

Storage

Follow the released-lot COA, SDS, label and stability statement for the actual physical form, concentration, container and grade. Do not transfer a ≤25°C finished-product label, freeze restriction or opened-ampoule rule unless the offered lot is that exact labelled presentation.

MOQ

1 kit (10 vials) per SKU

Lead time

14–21 days

Cerebrolysin is an identity used for a porcine-brain-derived, enzymatically hydrolysed protein fraction containing a heterogeneous population of peptides and amino acids. NCATS/GSRS classifies CAS 12656-61-0 and UNII 37KZM6S21G as structurally diverse and does not assign one formula or molecular weight. Marketed finished products and their clinical literature provide background on a defined manufacturer process and formulation; this 60 mg catalogue item is not automatically equivalent to those products. Clinical reviews vary by indication: Cochrane found no clear all-cause mortality benefit in acute ischaemic stroke and a signal for increased non-fatal serious adverse events, while other indications remain limited by heterogeneity and risk of bias. These data must not be converted into efficacy or safety claims for an unqualified RUO lot.

• Composition-fingerprint development, source/process comparability, molecular-size and amino-acid profiling, selected marker-peptide analysis and controlled cell-based neurobiology research
• These are laboratory applications, not clinical indications.

Marketed Cerebrolysin is hypothesized to exert neurotrophic or neuroprotective effects through multiple low-molecular-weight components and downstream plasticity pathways. Specific BDNF-like, NGF-like or other named activities do not establish the identity or concentration of individual active ingredients in this lot. Blood-brain-barrier, structural-plasticity and prolonged-effect explanations remain mixture-level pharmacodynamic hypotheses and cannot substitute for component characterization or prove equivalence to a clinical formulation.

• Not for human or veterinary use
• Porcine origin requires documented source-animal, tissue, transmissible-agent and process controls appropriate to the material and destination
• Chemical or fingerprint similarity does not establish sterility, bacterial-endotoxin control, injectable suitability or clinical safety
• Clinical systematic reviews of finished Cerebrolysin formulations include an acute-stroke signal for non-fatal serious adverse events; those data reinforce the need not to present this RUO lot as a treatment.

Interactions reported in the literature

• No patient drug-interaction or infusion-compatibility guidance is provided for this RUO material
• Finished-product label restrictions and clinical co-medication observations cannot be transferred without proving formulation equivalence
• Laboratory compatibility and assay interference must be tested in the exact matrix.

Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount

• 60 mg

Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.

Independent test fails? Full refund.

On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep

Ask for the current packet, not a generic certificate

• Require source species/tissue and manufacturing traceability, process controls, molecular-size distribution, orthogonal chromatographic and/or LC-MS fingerprint similarity to a qualified reference, amino-acid profile, quantitative peptide/protein or nitrogen content with its calculation basis, relevant physicochemical attributes, residual process reagents, contaminants and lot-specific stability
• Specify bioburden, sterility, bacterial endotoxin and viral/transmissible-agent controls separately where applicable
• Appearance, one HPLC trace or “≥99%” cannot qualify a heterogeneous hydrolysate.

Follow the released-lot COA, SDS, label and stability statement for the actual physical form, concentration, container and grade. Do not transfer a ≤25°C finished-product label, freeze restriction or opened-ampoule rule unless the offered lot is that exact labelled presentation.

State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.

• Identity: NCATS Inxight Drugs/GSRS for CAS 12656-61-0 and UNII 37KZM6S21G. Clinical-evidence context for finished formulations: 2023 Cochrane acute-ischaemic-stroke review, PMID 37818733/CD007026.pub7/PMC10565895; 2021 ESO/EAN post-stroke-cognitive-impairment guideline, PMID 34476868/PMC8564156; 2019 Cochrane vascular-dementia review, CD008900.pub3; 2023 TBI systematic review, PMID 36979317/PMC10046100; and the contrasting 2025 stroke meta-analysis, PMID 41018475/PMC12465088. Manufacturer product information defines its own 215.2 mg/ml prescription finished concentrate but does not qualify this separate 60 mg RUO lot.

1. 01

   Cerebrolysin for acute ischaemic stroke

   Cochrane Database of Systematic Reviews · 2023 · Cochrane systematic review (highest-tier evidence synthesis)

   Open source
2. 02

   European Stroke Organisation and European Academy of Neurology joint guidelines on post-stroke cognitive impairment

   European Journal of Neurology · 2021 · clinical practice guideline (joint society statement)

   Open source
3. 03

   Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial

   Stroke · 2016 · randomized controlled trial

   Open source
4. 04

   Cerebrolysin in Patients With Acute Ischemic Stroke in Asia: Results of a Double-Blind, Placebo-Controlled Randomized Trial

   Stroke · 2012 · randomized controlled trial (large multicenter, N>1000)

   Open source
5. 05

   Neuroprotective Treatment With Cerebrolysin in Patients With Acute Stroke: A Randomised Controlled Trial

   Journal of Neural Transmission · 2005 · randomized controlled trial

   Open source
6. 06

   Cerebrolysin in Mild-to-Moderate Alzheimer's Disease: A Meta-Analysis of Randomized Controlled Clinical Trials

   Dementia and Geriatric Cognitive Disorders · 2015 · meta-analysis of randomized controlled trials

   Open source
7. 07

   Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis

   Brain Sciences · 2023 · systematic review and meta-analysis

   Open source
8. 08

   Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 14 Randomized Controlled Trials

   Cureus · 2025 · systematic review and meta-analysis

   Open source

• How to read a peptide COA without confusing purity, identity and content
• Peptide purity versus peptide content: a buyer’s method map
• Questions to ask a research peptide supplier before the first purchase order